ONC
Beone Medicines·NASDAQ
--
--(--)
--
--(--)
4.97 / 10
Netural
Fund flow analysis registers a strong 7.74/10, reflecting positive momentum across all liquidity segments. Coupled with an overwhelmingly bullish analyst consensus (100% Buy rating from one analyst), the data indicate supportive market sentiment and potential near-term price pressure from inflows.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-04
InstitutionBarclays
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for ONC?
- ONC holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.97/10 (Netural).
